Presenilin 1 Mutation (A431V) Causing Features of Dementia with Lewy Bodies in a Chinese Family of Alzheimer’s Disease

Yanan Qiao1, Dantao Peng*, Miao Jin1 and Shuang Xue2

1Department of Neurology, China-Japan Friendship Hospital, Beijing 100029, PR China
2Department of Neurology, Center for Geriatric Medicine, China-Japan Friendship Hospital, Beijing 100029, PR China

Abstract

Aim: We reported a family with a presenilin 1 (PSEN1) gene mutation whose clinical manifestations are similar to the Dementia with Lewy bodies.

Methods: We collected peripheral blood of the proband, his daughter and 100 normal Chinese individuals and extracted genomic DNA. PCR-sequencing of PSEN1 and microtubule associated protein tau (MAPT) were performed. We also gave them transcranial sonography test (TCS).

Results: We found that the proband and his daughter were heterozygous for a mutation 1292nd base in exon 12 of PSEN1, causing the amino acid alanine substituted by valine at codon 431 (A431V), but this was not found in normal controls. Meanwhile hyperechogenicity of bilateral substantia nigra could be seen in the two patients with the right-left asymmetry index >1.15.

Conclusion: This study identified a mutation A431V in the PSEN1 gene in Chinese patients. We considered it might play an important role in familial Alzheimer’s disease leading clinical manifestations similar to DLB.

Keywords: Alzheimer’s disease; Dementia with lewy bodies; Mutation; Presenilin 1; Transcranial sonography

Introduction

Alzheimer’s disease (AD) and Dementia with Lewy bodies (DLB) are the two most common neurodegenerative diseases that cause progressive cognitive impairment. AD can be subdivided into sporadic type and familial type. The familial AD (FAD) is mostly early-onset, accounting for less than 5% of all AD cases, with Presenilin-1 (PSEN1) and Presenilin-2 (PSEN2) as its genes, of which PSEN1 stands at the top accounting for less than 5% of all AD cases, with Presenilin-1 (PSEN1) and Presenilin-2 (PSEN2) as its genes. Though, DLB is found mostly sporadic, without any confirmed genetic risk factor. Here, we describe a family presented with the clinical manifestations of DLB, who have a PSEN1 gene mutation.

Methods

Patients’ clinical data (Table 1)

The patients come from a Chinese family, which has 16 members, 8 males and 8 females. The pedigree is shown in Figure 1A. According to the revised 2005 International Criteria of Dementia with Lewy bodies [5], the proband (member II5) conformed to the diagnosis criteria of probable clinical DLB, and 8 females. The pedigree is shown in Figure 1A. According to the revised 2005 International Criteria of Dementia with Lewy bodies [5], the proband (member II5) conformed to the diagnosis criteria of probable clinical DLB, the proband who did not show any memory loss, personality changes, Parkinsonian symptoms, hallucinations and significantly fluctuant cognitive impairment at 56 years old without any head trauma or toxic exposure or other past illness history. Mini-mental state examination (MMSE) was 4 points, Montreal cognitive assessment (MOCA) 3 points, and the third part of United Parkinson’s Disease Rate Scale (UPDRS) 19 points.

The member II 2 developed memory loss and personality changes at the age of over 50, who was dead now. The member II 3 and II 4 developed clinical symptoms similar as DLB, who got memory declining, slow movement and hallucinations at the age of their 50 years, both bed-ridden now. But they refused to take any physical examination and blood test.

The member III3, female, 31 years old, once healthy, is the daughter of the proband who did not show any memory loss, personality changes, Parkinsonian symptoms and hallucination. Her MMSE scoring was 30 points, and MOCA 29 points (Figure 1B).

Genetic test

After complete description of the study to both of them, written informed consent was obtained from II 5 and III 3. The study was approved by the local ethics committee at China-Japan Friendship Hospital. We took blood samples and tested microtubule associated protein tau (MAPT) and PSEN1 genes. A healthy control group of 100 members was also employed for comparison including 48 males and 52 females, with an average age of 52.1, who were tested PSEN1 gene mutation and all have signed the informed consent.

Table 1: Patients’ demographic and clinical data.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Gender</th>
<th>Clinical Presentations</th>
<th>Past history</th>
<th>MMSE</th>
<th>MOCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>I 2</td>
<td>54</td>
<td>M</td>
<td>D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II 2</td>
<td>60</td>
<td>F</td>
<td>D, P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II 4</td>
<td>62</td>
<td>F</td>
<td>D, P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II 5</td>
<td>58</td>
<td>F</td>
<td>D, P, H</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III 3</td>
<td>31</td>
<td>F</td>
<td>D, P</td>
<td></td>
<td>30</td>
<td>29</td>
</tr>
</tbody>
</table>

**Table 1:** Patients’ demographic and clinical data.

**Aim:** We reported a family with a presenilin 1 (PSEN1) gene mutation whose clinical manifestations are similar to the Dementia with Lewy bodies.

**Methods:** We collected peripheral blood of the proband, his daughter and 100 normal Chinese individuals and extracted genomic DNA. PCR-sequencing of PSEN1 and microtubule associated protein tau (MAPT) were performed. We also gave them transcranial sonography test (TCS).

**Results:** We found that the proband and his daughter were heterozygous for a mutation 1292nd base in exon 12 of PSEN1, causing the amino acid alanine substituted by valine at codon 431 (A431V), but this was not found in normal controls. Meanwhile hyperechogenicity of bilateral substantia nigra could be seen in the two patients with the right-left asymmetry index >1.15.

**Conclusion:** This study identified a mutation A431V in the PSEN1 gene in Chinese patients. We considered it might play an important role in familial Alzheimer’s disease leading clinical manifestations similar to DLB.

**Keywords:** Alzheimer’s disease; Dementia with lewy bodies; Mutation; Presenilin 1; Transcranial sonography

**Introduction**

Alzheimer’s disease (AD) and Dementia with Lewy bodies (DLB) are the two most common neurodegenerative diseases that cause progressive cognitive impairment. AD can be subdivided into sporadic type and familial type. The familial AD (FAD) is mostly early-onset, accounting for less than 5% of all AD cases, with Presenilin-1 (PSEN1) and Presenilin-2 (PSEN2) as its genes, of which PSEN1 stands at the top accounting for less than 5% of all AD cases, with Presenilin-1 (PSEN1) and Presenilin-2 (PSEN2) as its genes. Though, DLB is found mostly sporadic, without any confirmed genetic risk factor. Here, we describe a family presented with the clinical manifestations of DLB, who have a PSEN1 gene mutation.

**Methods**

**Patients’ clinical data (Table 1)**

The patients come from a Chinese family, which has 16 members, 8 males and 8 females. The pedigree is shown in Figure 1A. According to the revised 2005 International Criteria of Dementia with Lewy bodies [5], the proband (member II5) conformed to the diagnosis criteria of probable clinical DLB, who is a 58 year old male and a National First-class Construction Engineer. He gradually developed cognitive decline and personality changes at the age of 54 years and began to exhibit Parkinsonian symptoms, hallucinations and significantly fluctuant cognitive impairment at 56 years old without any head trauma or toxic exposure or other past illness history. Mini-mental state examination (MMSE) was 4 points, Montreal cognitive assessment (MOCA) 3 points, and the third part of United Parkinson’s Disease Rate Scale (UPDRS) 19 points.

The member II 2 developed memory loss and personality changes at the age of over 50, who was dead now. The member II 3 and II 4 developed clinical symptoms similar as DLB, who got memory declining, slow movement and hallucinations at the age of their 50 years, both bed-ridden now. But they refused to take any physical examination and blood test.

The member III3, female, 31 years old, once healthy, is the daughter of the proband who did not show any memory loss, personality changes, Parkinsonian symptoms and hallucination. Her MMSE scoring was 30 points, and MOCA 29 points (Figure 1B).

**Genetic test**

After complete description of the study to both of them, written informed consent was obtained from II 5 and III 3. The study was approved by the local ethics committee at China-Japan Friendship Hospital. We took blood samples and tested microtubule associated protein tau (MAPT) and PSEN1 genes. A healthy control group of 100 members was also employed for comparison including 48 males and 52 females, with an average age of 52.1, who were tested PSEN1 gene mutation and all have signed the informed consent.

**Table 1:** Patients’ demographic and clinical data.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Gender</th>
<th>Clinical Presentations</th>
<th>Past history</th>
<th>MMSE</th>
<th>MOCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>I 2</td>
<td>54</td>
<td>M</td>
<td>D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II 2</td>
<td>60</td>
<td>F</td>
<td>D, P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II 4</td>
<td>62</td>
<td>F</td>
<td>D, P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II 5</td>
<td>58</td>
<td>F</td>
<td>D, P, H</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III 3</td>
<td>31</td>
<td>F</td>
<td>D, P</td>
<td></td>
<td>30</td>
<td>29</td>
</tr>
</tbody>
</table>

**Table 1:** Patients’ demographic and clinical data.
We used BigDye (Applied Biosystems; Axyprep DNA Gel EXtraction kit) for test. The primer 3 online design (Sangon Biotech Beijing Co., Ltd.) was adopted. The polymerase chain reaction (PCR) amplification reaction system was No. 12 exon primer sequence: sense 5'-TCCAGATTGAATGAACGTCTGT-3' , antisense 5'-AGACTTGGAAGGAAGCTGCA-3' . PCR products underwent electrophoresis on an ABI automated DNA sequencer (Perkin Elmer, Foster City, Calif). The data of electropherograms was analyzed using DNASTAR sequencing analysis software (Lasergene.v7.1).

**Transcranial sonography (TCS) test**

TCS was performed through the preauricular acoustic bone windows using a colour-coded phased-array ultrasound system equipped with a 2.5 MHz transducer (LOGIQ 9 ultrasound system). The ultrasound parameters were: penetration depth of 16 cm, dynamic range 50 dB. SN echogenic size measurements were performed on axial TCS scans automatically after manually encircling the outer circumference of substantia nigra (SN)'s echogenic area. SN echogenic sizes of less than $0.20 \text{ cm}^2$ are classified as normal. Additionally, echogenicity of thalami, lenticular nucleus and heads of caudate nucleus was investigated and classified as hyperechogenic when it was more intense than the surrounding white matter. For estimation of the right-left asymmetry index of SN echogenic sizes (SN+ R-L index), the larger size of bilateral measurements was divided by the smaller size. All TCS examinations were performed by one experienced sonographer (S.X.) who was blinded to diagnosis and clinical data of the patients.

**Results**

**Imaging and laboratory test data**

**Proband II 5:** Cranial magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) showed (Figure 2) global brain atrophy especially in hippocampus and temporal lobes as well as intracranial multiple focal ischemia lesions; D is the cranial MRA of proband showing no stenosis or occlusion of the intracranial blood vessels.

![Figure 1: A. The pedigree of the family; B. In PSEN1 genes of II5 and III3, mutation (C->T) occurred with the 1292nd base in the 12th exon This, resulted in the amino acids encoded by the 431st codon turning from alanine (Ala) into valine (Val).](image1)

![Figure 2: A-C is the cranial MRI of proband showing global brain atrophy especially significant in hippocampus and temporal lobes as well as intracranial multiple focal ischemia lesions; D is the cranial MRA of proband showing no stenosis or occlusion of the intracranial blood vessels.](image2)
proved that in addition to AD pathological features, Lewy Bodies can lead to symptoms like DLB. Some cases of autopsy reported DLB manifestations. Snider et al. [14] was no report about the mutation of PSEN1 gene (A431V) leading to DLB. Though III3 has no DLB manifestations, her tested DNA also has PSEN1 gene mutation. This needs further follow-up. So far, there is no clear evidence that the features of SN+ of DLB are the areas of SN+ ≥ 0.25 cm². It is noteworthy that by TCS hyperechogenicity of bilateral substantia nigra can be seen in the two patients of PSEN1 A431V mutation. TCS shows that 90% of the patients with Parkinson’s disease (PD) have abnormally enlarged SN+. In addition to PD, corticobasal ganglionic degeneration (CBD), DLB and many other neurodegenerative diseases also have SN+. Walter et al. [19] believed that the features of SN+ of DLB are the areas of SN+ ≥ 0.25 cm², and the bilateral asymmetry index <1.15. It is suggested that the SN+ is related to iron metabolism rather than Lewy body accumulation. In our research, the asymmetry index of SN echogenic sizes of both II 5 and III 3>1.15 and II 5 also has hyperechogenicity of bilateral lentiform nucleus. These are inconsistent with TCS features of the previously reported DLB. It is considered that our family is early-onset AD with DLB clinical features, not sporadic DLB, so the SN+ is not similar as sporadic DLB. But in a sense, it may give a hint that asymmetry of bilateral SN+ may be one of characteristic features in differentiating FAD with DLB from sporadic DLB.

Figure 3: A-B is the TCS imaging of proband showing hyperechogenicity of substantia nigra (SN+) in both sides which is 0.28 cm² of right midbrain and 0.31 cm² of left midbrain. C is the TCS imaging of III 3 showing SN+ in both sides which is 0.20 cm² of right and 0.27 cm² of left midbrain.

## Discussion

About 5% of patients with AD are FAD with genetic changes. PSEN1 gene mutation accounts for 18%-55% in the FAD families [2]. PSEN1 gene is located at 14q24.2 with the product of 3.1KB and the encoding area composed of 10 exons. It encodes a protein of 467 amino acids about 42-43 kDa long. So far, over 200 kinds of PSEN1 gene mutations have been found [6], of which the most are missense mutation at a single position. In our report, two patients of the family have C>T mutation of the 431st codon in the 12th exon at PSEN1 gene. Matsushita et al. [7] in 2002 found mutation at this position in an early-onset AD family, but not in normal controls. As a result, the mutation at this position was considered as a pathological mutation. Therefore, the family of our research was finally diagnosed as FAD caused by mutation of the 12th exon of PSEN1 gene. However, the patients of the family mentioned in Matsushita’s article showed no DLB symptoms. It might be related to the mild cognitive impairment at that time. But Matsushita did not describe the detail about the following up of the family. So whether the patients developed DLB symptoms at the late stage of the disease was not clear.

More and more researches [8-13] proved that the mutation of PSEN1 is widely involved in the AD pathological processes which include senile plaques (SPs), neurofibrillary tangles (NFT) and loss of neurons and synapses: (1) The mutation of PSEN1 can selectively cause the increasing of β-amyloid protein-42 by two or three times, and enhance the aggregation of pathological tau nerve filaments; (2) The abnormal modification of tau protein which relates to the formation of NFT has a positive correlation with the severity of dementia of AD. The mutation of PSEN1 can combine with microtubule to promote excessive phosphorylation of tau protein by glycogen synthase kinase-3β (GSK-3β).

In this family, the proband II5 met the revised international clinical diagnosis criteria of DLB by McKeith et al. [5] in 2005. Other members of the family (II2 and II4) also have the clinical manifestations similar to DLB. Though II3 has no DLB manifestations, her tested DNA also has PSEN1 gene mutation. This needs further follow-up. So far, there was no report about the mutation of PSEN1 gene (A431V) leading to DLB manifestations. Snider et al. [14] once reported DLB symptoms appearing in PSEN1 gene F5170 mutation. Ishikawa [15] reported a case that the deletion of the 440th position in PSEN1 leads to the loss of threonine, which also appears as DLB. It is not sure why the mutation of gene PSEN1 can lead to symptoms like DLB. Some cases of autopsy [14-16] proved that in addition to AD pathological features, Lewy Bodies (LBs) which is the key pathological feature of DLB is also a very frequent coexistent pathologic abnormality in FAD. It can be found wide spread in the brainstem, limbic areas, nigra and neocortex. Meanwhile, these pathological changes of LBs occur more frequently in FAD related to gene PSEN1 mutation than FAD related to Presenilin-2 gene mutation and sporadic AD [17]. It was speculated that in the normal condition PSEN1 plays an important role in certain interations or interfuncions between β-amyloid and α-synuclein. This has been proved by Winslow [17] using immunoelectron microscopy found that PSEN1 together with α-synuclein and β-amyloid are closely related on the presynaptic vesicles, surfaces of mitochondria and plasma membrane. Aggregation of α-synuclein into Lewy bodies (LBs) can also be induced by PSEN1 mutation to an equal extent as β-amyloid pathology [15]. These above studies and assumptions provided proofs to the relationships between PSEN1 and α-synuclein and could state the mechanism of the AD patients of PSEN1 gene mutation presented with DLB clinical features.

It is noteworthy that by TCS hyperechogenicity of bilateral substantia nigra can be seen in the two patients of PSEN1 A431V mutation. TCS shows that 90% of the patients with Parkinson’s diseases (PD) have abnormally enlarged SN+ [18]. In addition to PD, corticobasal ganglionic degeneration (CBD), DLB and many other neurodegenerative diseases also have SN+. It was speculated that in the normal condition PSEN1 plays an important role in certain interations or interfuncions between β-amyloid and α-synuclein. This has been proved by Winslow [17] using immunoelectron microscopy found that PSEN1 together with α-synuclein and β-amyloid are closely related on the presynaptic vesicles, surfaces of mitochondria and plasma membrane. Aggregation of α-synuclein into Lewy bodies (LBs) can also be induced by PSEN1 mutation to an equal extent as β-amyloid pathology [15]. These above studies and assumptions provided proofs to the relationships between PSEN1 and α-synuclein and could state the mechanism of the AD patients of PSEN1 gene mutation presented with DLB clinical features.

## Conclusion

This research reported that the early-onset FAD of PSEN1 gene A431V mutation has the clinical features of DLB for the first time. It helps understanding clinical manifestations of FAD with PSEN1 mutation and suggests that when we meet with familial DLB, early-onset FAD with PSEN1 mutation should be considered and TCS may be one of important methods to differentiate them. As a limitation of this research, the gene has not been detected in other family members, especially the other two patients. Furthermore, though positive in gene test, II3 has no symptoms. We will further follow up for more clinical data.
Acknowledgement

The authors are thankful to the participants, their families and healthy volunteers. The authors are also grateful to the members of Sangon Biotech Beijing Co., Ltd to examine the blood samples.

References